These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 36619222)

  • 21. Development of 3D culture models of plexiform neurofibroma and initial application for phenotypic characterization and drug screening.
    Kraniak JM; Chalasani A; Wallace MR; Mattingly RR
    Exp Neurol; 2018 Jan; 299(Pt B):289-298. PubMed ID: 29055717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience.
    Espírito Santo V; Passos J; Nzwalo H; Carvalho I; Santos F; Martins C; Salgado L; Silva CE; Vinhais S; Vilares M; Salgado D; Nunes S
    J Neurooncol; 2020 Apr; 147(2):459-463. PubMed ID: 32108293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.
    Jiang C; Kumar A; Yu Z; Shipman T; Wang Y; McKay RM; Xing C; Le LQ
    J Clin Invest; 2023 Jun; 133(12):. PubMed ID: 37140985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas.
    Gross AM; Dombi E; Wolters PL; Baldwin A; Dufek A; Herrera K; Martin S; Derdak J; Heisey KS; Whitcomb PM; Steinberg SM; Venzon DJ; Fisher MJ; Kim A; Bornhorst M; Weiss BD; Blakeley JO; Smith MA; Widemann BC
    Neuro Oncol; 2023 Oct; 25(10):1883-1894. PubMed ID: 37115514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selumetinib in Children with Inoperable Plexiform Neurofibromas.
    Gross AM; Wolters PL; Dombi E; Baldwin A; Whitcomb P; Fisher MJ; Weiss B; Kim A; Bornhorst M; Shah AC; Martin S; Roderick MC; Pichard DC; Carbonell A; Paul SM; Therrien J; Kapustina O; Heisey K; Clapp DW; Zhang C; Peer CJ; Figg WD; Smith M; Glod J; Blakeley JO; Steinberg SM; Venzon DJ; Doyle LA; Widemann BC
    N Engl J Med; 2020 Apr; 382(15):1430-1442. PubMed ID: 32187457
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and Efficacy of Mek Inhibitors in the Treatment of Plexiform Neurofibromas: A Retrospective Study.
    Cacchione A; Fabozzi F; Carai A; Colafati GS; Baldo GD; Rossi S; Diana M; Megaro G; Milano GM; Macchiaiolo M; Crocoli A; De Ioris MA; Boccuto L; Secco DE; Zama M; Agolini E; Tomà P; Mastronuzzi A
    Cancer Control; 2023; 30():10732748221144930. PubMed ID: 36598023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selumetinib for symptomatic, inoperable plexiform neurofibromas in children with neurofibromatosis type 1: A national real-world case series.
    Coltin H; Perreault S; Larouche V; Black K; Wilson B; Vanan MI; Gupta AA; Morgenstern DA; Parkin PC; Bouffet E; Ramaswamy V
    Pediatr Blood Cancer; 2022 Aug; 69(8):e29633. PubMed ID: 35289492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.
    Church C; Fay CX; Kriukov E; Liu H; Cannon A; Baldwin LA; Crossman DK; Korf B; Wallace MR; Gross AM; Widemann BC; Kesterson RA; Baranov P; Wallis D
    Acta Neuropathol Commun; 2024 Jun; 12(1):102. PubMed ID: 38907342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic analyses of mosaic neurofibromatosis type 1 with giant café-au-lait macule, plexiform neurofibroma and multiple melanocytic nevi.
    Hida T; Idogawa M; Okura M; Sugita S; Sugawara T; Sasaki Y; Tokino T; Yamashita T; Uhara H
    J Dermatol; 2020 Jun; 47(6):658-662. PubMed ID: 32246533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dramatic Improvement of a Massive Plexiform Neurofibroma After Administration of Selumetinib.
    Passos J; Nzwalo H; Azevedo M; Tavares M; Nunes S
    Pediatr Neurol; 2020 Apr; 105():69-70. PubMed ID: 31917098
    [No Abstract]   [Full Text] [Related]  

  • 31. Selumetinib: the first ever approved drug for neurofibromatosis-1 related inoperable plexiform neurofibroma.
    Mukhopadhyay S; Maitra A; Choudhury S
    Curr Med Res Opin; 2021 May; 37(5):789-794. PubMed ID: 33683166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Size of tooth crowns and position of teeth concerning the extension of facial plexiform neurofibroma in patients with neurofibromatosis type 1.
    Friedrich RE; Giese M; Stelljes C; Froeder C; Scheuer HA
    Anticancer Res; 2012 May; 32(5):2207-14. PubMed ID: 22593511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A chance to cut is a chance to cure: complete resection of an atypical neurofibroma prevents further progression to malignancy.
    Vaassen P; Feldkamp A; Scholz M; Blau T; Dürr NR; Rosenbaum T
    Childs Nerv Syst; 2023 Nov; 39(11):3301-3304. PubMed ID: 37344677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early administration of imatinib mesylate reduces plexiform neurofibroma tumor burden with durable results after drug discontinuation in a mouse model of neurofibromatosis type 1.
    Armstrong AE; Rhodes SD; Smith A; Chen S; Bessler W; Ferguson MJ; Jiang L; Li X; Yuan J; Yang X; Yang FC; Robertson KA; Ingram DA; Blakeley JO; Clapp DW
    Pediatr Blood Cancer; 2020 Aug; 67(8):e28372. PubMed ID: 32459399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of Plexiform Neurofibromas with MEK Inhibitors: First Results with a New Therapeutic Option.
    Vaassen P; Dürr NR; Rosenbaum T
    Neuropediatrics; 2022 Feb; 53(1):52-60. PubMed ID: 34905788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities.
    Klesse LJ; Jordan JT; Radtke HB; Rosser T; Schorry E; Ullrich N; Viskochil D; Knight P; Plotkin SR; Yohay K
    Oncologist; 2020 Jul; 25(7):e1109-e1116. PubMed ID: 32272491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of Ras signaling pathway proteins and developmental factors in peripheral nerve sheath tumors of patients with neurofibromatosis type 1.
    Hagel C; Nörnberg LKN; Friedrich RE
    Clin Neuropathol; 2023; 42(4):150-160. PubMed ID: 37226590
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of Cardiac Function by Echocardiographic Global Longitudinal Strain in a Cohort of Children with Neurofibromatosis Type 1 Treated with Selumetinib.
    Caiffa T; Tessitore A; Magnolato A; Petz M; Bobbo M; Chicco D; D'Agata Mottolese B; Porcari A; Barbi E; Sinagra G; Bruno I
    Paediatr Drugs; 2023 Mar; 25(2):217-224. PubMed ID: 36529809
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selumetinib in the Treatment of Symptomatic Intractable Plexiform Neurofibromas in Neurofibromatosis Type 1: A Prospective Case Series with Emphasis on Side Effects.
    Baldo F; Grasso AG; Cortellazzo Wiel L; Maestro A; Trojniak MP; Murru FM; Basso L; Magnolato A; Bruno I; Barbi E
    Paediatr Drugs; 2020 Aug; 22(4):417-423. PubMed ID: 32533336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-coding RNA ANRIL and the number of plexiform neurofibromas in patients with NF1 microdeletions.
    Mußotter T; Kluwe L; Högel J; Nguyen R; Cooper DN; Mautner VF; Kehrer-Sawatzki H
    BMC Med Genet; 2012 Oct; 13():98. PubMed ID: 23101500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.